HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents.

AbstractOBJECTIVE:
To assess patient satisfaction with and preference for naratriptan hydrochloride therapy over previous "nontriptan" therapy for migraines.
DESIGN AND SETTING:
Open-label study conducted at 15 primary care clinics.
PATIENTS:
One hundred forty-three adults meeting International Headache Society diagnostic criteria for migraine who were not using triptans as first-line therapy for migraines were enrolled; 115 completed the study. INTERVENTION AND OUTCOME ASSESSMENTS: At baseline, satisfaction with current migraine therapy was assessed. Patients were provided with naratriptan hydrochloride, 2.5 mg, to treat 3 migraines and diaries to record headache symptoms and response to treatment. After treating 3 migraines, satisfaction with naratriptan therapy and preference for either previous or naratriptan therapy were assessed.
RESULTS:
Eighty-nine (62%) of 143 patients had previous exposure to triptans, with lack of prescribing (55%) as the primary reason for not continuing their use as first-line therapy. Medications used for first-line therapy included simple analgesics (59%), combination products (46%), and narcotics (13%). After treating 3 migraines with naratriptan, satisfaction with migraine therapy increased from 47% to 75%. Sixty-three percent of patients preferred naratriptan therapy over their previous nontriptan therapy, 27% preferred their previous therapy, and 10% had no preference. The main reasons for preference for naratriptan therapy were "relieves pain effectively" (86%) and "restores ability to function/perform task" (81%).
CONCLUSION:
Naratriptan for first-line migraine therapy was preferred by most patients over previous nontriptan therapy.
AuthorsC Powers, S Szeto, D Pangtay, T Bort, M Cervi, R Cady
JournalArchives of family medicine (Arch Fam Med) Vol. 9 Issue 8 Pg. 753-8 (Aug 2000) ISSN: 1063-3987 [Print] United States
PMID10927717 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Indoles
  • Piperidines
  • Serotonin Receptor Agonists
  • Tryptamines
  • Vasoconstrictor Agents
  • naratriptan
Topics
  • Adult
  • Aged
  • Female
  • Humans
  • Indoles (therapeutic use)
  • Male
  • Middle Aged
  • Migraine Disorders (drug therapy)
  • Patient Satisfaction (statistics & numerical data)
  • Piperidines (therapeutic use)
  • Serotonin Receptor Agonists (therapeutic use)
  • Treatment Outcome
  • Tryptamines
  • Vasoconstrictor Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: